The Dual Nature of Type I and Type II Interferons.
Lee AJ, Ashkar AA. · 2018
Read The Dual Nature of Type I and Type II Interferons. by Lee AJ, Ashkar AA. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6141705.txt.
Introduction
Lee and Ashkar wrote a review in Frontiers in Immunology on the dual nature of interferons, key signaling proteins of the immune system. Type I and type II interferons are central to fighting virus infection. Without them, people and animals face worse infections and lower survival.
The review shows that these proteins do more than attack viruses. They also tune the immune response up and down. That tuning limits virus growth and starts the right defense. It then reins the response in to spare healthy tissue. The authors argue both jobs are vital during infection. Readers get a balanced view of molecules often cast as purely protective.
Catalog record
| CREATOR | Lee AJ, Ashkar AA. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Dual Nature of Type I and Type II Interferons By Amanda J. Lee, Ali A. Ashkar Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2018.02061 ABSTRACT Type I and type II interferons (IFN) are central to both combating virus infection and modulating the antiviral immune response. Indeed, an absence of either the receptor for type I IFNs or IFN-y have resulted in increased susceptibility to virus infection, including increased virus replication and reduced survival. However, an emerging area of research has shown that there is a dual nature to these cytokines. Recent evidence has demonstrated that both type I and type II IFNs have immunoregulatory functions during infection and type II immune responses. In this review, we address the dual nature of type I and type II interferons and present evidence that both antiviral and immunomodulatory functions are critical during virus infection to not only limit virus replication and initiate an appropriate antiviral immune response, but to also negatively regulate this response to minimize tissue damage. Both the activating and negatively regulatory properties of type I and II IFNs work in concert with each other to create a balanced immune response that combats the infection while minimizing collateral damage. INTRODUCTION Type I and II interferons (IFN) are cytokines produced during virus infection that are integral for regulating the immune response. Type I IFNs are well known for their ability to directly induce an antiviral response within infected and surrounding cells through the upregulation of molecules that can antagonize virus replication (1). As they are produced rather early on during an infection, type I IFNs are also essential for activating the antiviral innate immune response, such as natural killer (NK) cell effector functions (2). Type II IFN, known as IFN-γ, while sharing a similar nomenclature to type I IFN, signals through a different receptor and has effects that are independent from type I IFN. As a part of the innate immune response, they are predominantly produced by natural killer cells during infection (2). IFN-γ, like type I IFN, promotes antiviral immunity through its regulatory effects on the innate immune response and acts as a key link between the innate immune response and activation of the adaptive immune response (3). Beyond their antiviral effects, a growing amount of evidence suggests that type I and type II IFNs have immunoregulatory functions that are critical for dampening immunopathogenic mechanisms and minimizing collateral damage from the infection. Altogether, this review will build a framework and provide evidence demonstrating that these two cytokines are both critical for limiting virus replication and promoting a beneficial virus limiting response, while simultaneously dampening immunopathology. If we consider the world outside of virus infections, however, this fundamental duality of type I and II IFNs can be applied to numerous pathological processes, ranging from allergy to autoimmune diseases. Type I and II IFN production and signaling Type I IFNs consist of a group of structurally similar cytokines and include 13–14 subtypes of IFN-α along with IFN-β, IFN-ε, IFN-κ, IFN-ω, IFN-δ, IFN-ζ, and IFN-τ (4, 5). As part of the innate immune antiviral response, these cytokines are rapidly produced after pattern-recognition receptor (PRR) stimulation (5). Current research suggests that an initial wave of IFN-β and IFN-α4 is produced and dependent upon IRF3 phosphorylation and NFκb activation (6–8). The initial type I IFN wave subsequently induces IRF7 phosphorylation and results in a positive feedback loop of increasing type I IFN release. Once produced, these cytokines all signal through the same receptor, the type I IFN receptor (IFNAR). IFNAR is composed of two subunits—IFNAR1 and IFNAR2—which when bound to type I IFN are endocytosed and activate their associated tyrosine kinases, Tyk2 and Jak1 (4, 9). The classical signaling cascade results in phosphorylation of STAT2 and STAT1, which forms a complex with IRF9, known as the IFN-stimulated gene factor 3 (ISGF3) (4). ISGF3 then leads to expression of IFN-stimulated genes (4). Beyond ISGF3, type I IFNs can also induce phosphorylation and dimerization of STAT3, STAT4, STAT5, and STAT6 and has been shown to induce activation of Rap1, CrkL, Map kinases, IRS-1 and -2, Vav, RAC1, and PI3-kinase signal transduction pathways (4, 10–14). Interestingly, IFN-β has been shown to additionally signal through the IFNAR1 subunit independent from IFNAR2 and carries through a non-canonical signaling pathway (15). Type II IFN is predominantly produced by NK cells during the antiviral innate immune response (16). A multitude of evidence has shown that type I IFN, IL-12, IL-15, and IL-18 are all capable of inducing IFN-γ production from NK cells (17). NK cell IFN-γ is dependent upon STAT4 phosphorylation for its production. Once released, IFN-γ signals through the IFN-γ receptor (IFNGR), composed of IFNGR1 and IFNGR2 subunits. In the classical signaling pathway, ligation of IFN-γ to the IFNGR leads to activation of JAK1 and JAK2, resulting in homodimerization and phosphorylation of STAT1 (18). However, like type I IFN, IFN-γ has also been shown to signal through alternative pathways, including STAT4, Erk1/2, Pyk2, and CrkL, among others (18). Type I IFN: mastering the antiviral response Type I IFN is one of the first cytokines produced during a virus infection. In the context of HSV-2 infection, for example, there is an initial wave of IFN-β production at 12 h post-infection, followed by both IFN-β and IFN-α production at 48 h post-infection (19, 20). This early production of type I IFN is critical for induction of both an antiviral response within infected and target cells, as well as activation of innate immune cells that will ultimately serve to control virus replication and activate the adaptive immune response to both clear the infection and generate memory to create a rapid response against future infections (21). Type I IFN is a well-known stimulator of antiviral genes targeted against preventing virus replication from within target cells. When their production is stimulated by virus infection, type I IFN can act in an autocrine, paracrine, or systemic fashion. Their protective role during virus infection is highlighted by the increased mortality observed in mice deficient in the type I IFN receptor (Ifnar−/−) in comparison to their control counterparts when infected with a virus (22, 23). Upon ligation to its receptor, type I IFN has been shown to induce upwards of 300 ISGs. Of these 300 genes, 51 were found to contribute to host defense, while other genes contributed to inflammation, signaling, transcription, and immunomodulation, among other activities (24, 25). Further, De Veer et al. examined the ability of specific ISGs or combinations of ISGs to inhibit virus replication through overexpression of individual ISGs prior to virus infection (24). They found that many ISGs were capable of inhibiting virus replication, with some acting on a wide range of viruses, while others were only effective against particular viruses (24). Interestingly, they found that select ISGs enhanced virus replication in their experimental system (24). Antiviral ISGs can hinder virus replication through several mechanisms. Protein kinase R, for example, inhibits cellular translational functions (1). 2′5 OAS and RNaseL, on the other hand, degrade RNA (26, 27). Other ISG antiviral activities can prevent virion release, inhibit virus entry, and inhibit virus transcription (28). Apart from their induction of antiviral ISGs, type I IFNs are key regulators of the innate immune response. Within the type I